IMAGIO® | OA/US Breast Imaging System

Imagio® delivers diagnostic confidence at the point of care

Despite the rapid advancement in breast imaging modalities, the current clinical pathway is inefficient, resulting in multiple procedures, inconclusive results, and a negative patient experience.

Imagio® represents the first real alternative to this complexity by providing diagnostic confidence earlier in the care pathway.

Getting Started

Access our brochures, ebook and when you're ready, schedule a demo.

Access desired Audience

Information to educate Radiologists, patients experiences, a breakdown of improved practice efficiency and more.

Laser light in. Sound out.

The new imaging modality to diagnose breast cancer in real-time.

By transmitting laser light through suspicious breast tissue, Imagio® returns ultrasound signals that can display both functional and anatomical information about the relative blood and oxygen concentration. This enables clinicians to differentiate malignant and benign tissue: in a full-color display.

Share this page

Facebook
X
LinkedIn

OA/US Case Examples

View case examples below of OA/US imaging and diagnosis produced by Imagio® and SenoGram®.

For more detailed examples, request a consultation.

luminal b
Luminal B Cancer

Case Example 1: 

77-year-old female recalled for diagnostic imaging on new 0.7 cm mass seen on right breast. Ultrasound imaging demonstrates a round mass with an echogenic rim and minimal doppler signal.

case1-slide2
See OA/US Image

Case Example 1: Observations

With OA, we can see deoxygenated hemoglobin both internally to the mass and externally in the boundary and periphery of the mass as an intense pink blush as it invades normal breast tissues.

On the combined map (upper middle) and relative map (lower middle), and even in the total hemoglobin map (lower left), we can see perpendicular vessels in the peripheral zone that enter through the boundary zone. These are characteristics seen in cancerous masses.

case1-slide2
Diagnosis

Invasive Breast Carcinoma Grade II – with Lobular Feature

  • ER+
  • HER2-
  • PR+
  • Ki67=15%

This patient was up-classified to a BI-RADS 5. Luminal B masses typically present with both internal and external OA features.

case2-slide1
Triple Negative Cancer

Case Example 2: 

48-year-old female, presented with an abnormal mammogram/tomo. 1.9 cm mass seen on ultrasound, negative doppler.

case2-slide2
See OA/US Image

Case Example 2: Observations

Deoxygenated hemoglobin internal to the mass is represented by intense disorganized or polymorphic pink colorization seen on the 6-up image.

These are typical malignant characteristics on OA which are represented on the combined map (upper middle), total hemoglobin (lower left) and relative map (lower middle).

case2-slide2
Diagnosis

Invasive Ductal Carcinoma Grade III

  • ER-
  • HER2-
  • PR-
  • Ki67=80%


The Mass was up-classified to BI-RADS 4C. Biopsy confirmed triple negative cancer. TNC masses typically present with intense deoxygenated mainly internal vessels. Masses with high Ki67 tend to have a lot of internal vessels mainly in the internal and boundary zones, unless there is necrosis.

case3-slide1
Fibroadenoma

Case Example 3: 

24-year-old female presents with a 2.7 cm palpable mass in her right breast. Ultrasound imaging demonstrates a solid mass with negative color doppler.

case3-slide2
See OA/US Image

Case Example 3: Observations

The mass does not reveal any suspicious internal signal on the combined map with paired draping vessels anteriorly and a deoxygenated vessel posteriorly. Draping vessels are typical benign characteristics when seen in OA, as the mass pushes the vessels away versus penetrating or feeding the mass in a cancer OA image. 

Balanced mixture of well-organized red and green vessels, small in size with large periphery vessels as seen in the OA Relative map.

case3-slide2
Diagnosis
  • No biopsy - LOM BI-RADS 2
  • Fibroadenoma

Mass down-classified from BI-RADS 3 to BI-RADS 2. Typical OA characteristics seen in fibroadenomas.
case4-slide1
Fibrocystic Inflamed Cyst

Case Example 4:

53-year-old female, called back for diagnostic imaging. A 5 mm mass seen on ultrasound with complex, negative doppler signal.

case4-slide2
See OA/US Image

Case Example 4: Observations

OA imaging demonstrates an increase in an intense pink colorization with an “eggshell sign” seen on the short wavelength. The raw short wavelength image represents deoxygenated hemoglobin and the long wavelength map in the lower right represents the raw oxygenated Hgb from the two lasers.

The eggshell pattern on the short wavelength is a benign feature, in addition to the intense pink colorization appearing as a uniform bloom versus a polymorphic (disorganized) pattern often seen with malignant masses. 

Angiogenesis can be malignant or benign. Here we see physiologic angiogenesis associated with acute inflammation.

case4-slide2
Diagnosis
  • Fibrocystic, Proliferative
  • Inflamed Cyst

This patient was biopsied, and results were fibrocystic inflamed cyst. Mass down-classified from BI-RADS 4A to BI-RADS 2.
case5-slide1
Luminal A Cancer

Case Example 5:

59-year-old female presents with a new mammographic asymmetry on the left breast.

A 1.2 cm mass is seen on ultrasound with some doppler signal along periphery of mass.

case5-slide2
See OA/US Image

Case Example 5: Observations

With OA imaging we can see negative internal findings but positive external features in the boundary and peripheral zones.

We can see feeding and draining vessels or “whiskers” in the boundary and peripheral zones on OA.

Radiating vessels continue from the peripheral zone into the boundary zone and count as features in both zones.

case5-slide2
Diagnosis

Invasive Ductal Carcinoma Grade I

  • ER+
  • HER2-
  • PR-
  • Ki67=10%

The mass was up-classified to BI-RADS 5. Unlike TNC, luminal A masses typically present with external features in the boundary and peripheral zones and no OA internal features. Typically, luminal A masses have a low Ki67 and tend to have less internal angiogenesis and deoxygenation.
case6-slide1
HER2+ Cancer

Case Example 6:

58-year-old female presents with a new mammographic finding. On ultrasound, we can see a 1.2 cm mass with minimal Doppler signal internally and just outside the mass in the boundary zone.

case6-slide2
See OA/US Image

Case Example 6: Observations

In the OA imaging we can see an increase in deoxygenated hemoglobin both internally to the mass and in the boundary zone of the mass as seen on the relative and total hemoglobin OA maps.

case6-slide2
Diagnosis

Invasive Ductal Carcinoma Grade III

  • ER-
  • HER2+
  • PR-
  • Ki67=N/A

This mass was biopsied and was a grade III invasive ductal carcinoma, HER2 positive molecular subtype breast cancer.

AI-based decision support

Accurately assign diagnostic BI-RADS

Proven to make clinicians more accurate, our proprietary SenoGram® provides AI-driven decision support in assessing likelihood of malignancy (LOM).

Hear it straight from our clients

Basak-Dogan-MD
“This is game-changing for breast cancer imaging in that we get functional information—that we would normally get from advanced imaging—but with ultrasound.”
UT Texas Logo
Basak Dogan, MD
Director of Research at UT Southwestern Medical Center's Holden C. Simmons Comprehensive Cancer Center
Jeroen-Veltman-MD-PhD
“This makes you a better radiologist, having more and deeper information. We can decide more certainly with this anatomic and functional information what is the right path for the patient.”
pink ribbon
Jeroen Veltman, MD, PhD
Assistant Professor, Chair, Dutch College of Breast Imaging (DCBI)

A simple transition that improves practice efficiency and profitability

Imagio® integrates into your existing diagnostic workflow over time, similar to how tomosynthesis was introduced. The technology can be easily adopted with the support of SenoGram® and training from a leading Breast Ultrasound expert, Dr. Tom Stavros through Seno University.

References

  1. Seiler SJ, Neuschler EI, Butler RS, Lavin PT, Dogan BE. Optoacoustic imaging with decision support for differentiation of benign and malignant breast masses: A 15-reader retrospective study. AJR Am J Roentgenol. December 7, 2022.